What is Alltrna?
Headquartered in Cambridge, Massachusetts, Alltrna operates as a Flagship Pioneering company dedicated to the systematic exploration of transfer RNA (tRNA) biology. The firm is pioneering a novel class of tRNA medicines designed to regulate the protein universe, offering a transformative approach to resolving complex diseases. By targeting the fundamental mechanisms of protein synthesis, Alltrna distinguishes itself within the biotechnology sector as a leader in precision therapeutics, moving beyond traditional modalities to address previously undruggable genetic targets.
How much funding has Alltrna raised?
Alltrna has raised a total of $109M across 1 funding round:
Series B
$109M
Series B (2023): $109M with participation from Flagship Pioneering
Key Investors in Alltrna
Flagship Pioneering
Flagship Pioneering is a prominent life sciences venture capital firm that specializes in the creation and development of breakthrough biotechnology and sustainability companies.
What's next for Alltrna?
With the successful closure of this funding, Alltrna is poised to scale its operational infrastructure and advance its lead candidates toward human clinical trials. The strategic allocation of this capital will likely focus on expanding the company's proprietary platform capabilities and strengthening its intellectual property portfolio. As the firm continues to map the protein universe, the focus will shift toward establishing key partnerships and refining its manufacturing processes to support long-term commercial viability in the competitive landscape of RNA-based therapeutics.
See full Alltrna company page
